This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Austin-based Saturn V Capital disclosed a new Q3 position in Pharvaris N.V., acquiring 886,332 shares worth about $22.1 million (roughly 4.9% of its 13F AUM) as part of a $456 million fund with 17 U.S. equity holdings. Pharvaris is a clinical-stage biotech (market cap ≈ $1.6bn) developing oral therapies for hereditary angioedema with multiple programs (PHA121, PHVS416, PHVS719), a cash runway of about €329m into H1 2027 and a positive RAPIDe-3 topline showing median symptom relief in 1.3 hours, but it remains pre-revenue with widening R&D losses. The stake signals Saturn V’s high-conviction exposure to clinical-stage biotech risk—consistent with its concentrated biotech profile—and underscores that meaningful upside for investors depends on upcoming late-stage clinical readouts.

Analysis

Saturn V Capital initiated a new Q3 position in Pharvaris N.V. (PHVS), acquiring 886,332 shares valued at $22.1 million and representing about 4.9% of its $456 million 13F AUM; the holding expands the fund's reportable U.S. equity positions to 17 and sits outside its top-five allocations. Pharvaris is a clinical-stage biotech with a $1.6 billion market cap, shares at $25.35 (up 33% over the past year) and reported a TTM net loss of $163.7 million while remaining pre-revenue. The company reported €329 million in cash as of September 30, which management says funds operations into H1 2027, and recent R&D spend widened to €29.8 million last quarter from €25.8 million a year earlier, underlining ongoing burn. RAPIDe-3 Phase 3 topline was reported positive with a median time to symptom relief of 1.3 hours, making upcoming late-stage data and regulatory paths the primary value drivers while balance-sheet runway and potential dilution are the main near-term risks.

Key Decisions for Investors

• Treat PHVS as a high-risk, catalyst-driven biotech exposure and limit position size relative to overall portfolio given the company is pre-revenue and Saturn V’s stake equals 4.9% of its 13F AUM
• Monitor upcoming clinical milestones and regulatory catalysts closely—the RAPIDe-3 topline was positive but meaningful upside depends on confirmatory late-stage results and commercialization signals, watch for announcements and trial readouts
• Track cash burn and financing risk (€329m runway into H1 2027 versus rising R&D spend); consider hedging or staging investment to avoid dilution risk if the company seeks new capital before pivotal approvals